Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a major worldwide health problem. Recent studies suggest that the gut microbiota influences NAFLD pathogenesis. Here, a murine model of high-fat diet-induced (HFD-induced) NAFLD was used, and the effects of alterations in the gut microbiota on NAFLD were determined. Mice treated with antibiotics or tempol exhibited altered bile acid composition, with a notable increase in conjugated bile acid metabolites that inhibited intestinal farnesoid X receptor (FXR) signaling. Compared with control mice, animals with intestine-specific Fxr disruption had reduced hepatic triglyceride accumulation in response to a HFD. The decrease in hepatic triglyceride accumulation was mainly due to fewer circulating ceramides, which was in part the result of lower expression of ceramide synthesis genes. The reduction of ceramide levels in the ileum and serum in tempol- or antibiotic-treated mice fed a HFD resulted in downregulation of hepatic SREBP1C and decreased de novo lipogenesis. Administration of C16:0 ceramide to antibiotic-treated mice fed a HFD reversed hepatic steatosis. These studies demonstrate that inhibition of an intestinal FXR/ceramide axis mediates gut microbiota-associated NAFLD development, linking the microbiome, nuclear receptor signaling, and NAFLD. This work suggests that inhibition of intestinal FXR is a potential therapeutic target for NAFLD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hence, treatment with antibiotics ameliorates high-fat-diet-induced NAFLD in mice55.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [55]
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [257]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Functional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
Bäckhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605374104 · Cited by 2,615
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Human gut microbiota in obesity and after gastric bypass
Zhang, H., DiBaise, J. K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., Parameswaran, P., Crowell, M. D., Wing, R., Rittmann, B. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812600106 · Cited by 1,880
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · cited 1×
“FXR, the central sensor and regulator for the biosynthesis and enterohepatic recycling of bile acids, plays a pivotal role in the control of lipid metabolism (42–45).”
Self-citation
Research works printed but not linked: 1
- 10.1172/jci21025 · DOI · Paper page
Cited by
Items 201–300 of 746
Developments in bile salt based therapies: A critical overview
Donkers, J. M., Abbing, R. L. P. R., & van de Graaf, S. F. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.018 · Cited by 80
Ciaula, A. D., Bonfrate, L., Baj, J., Khalil, M., Garruti, G., Stellaard, F., Wang, H. H., Wang, D. Q. ‐., & Portincasa, P. (2022) · Nutrients · doi:10.3390/nu14234950 · Cited by 82
Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either
Hartmann, P., Chu, H., Duan, Y., & Schnabl, B. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00370.2018 · Cited by 79
Intestinal Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease
Liu, L., Yin, M., Gao, J., Yu, C., Lin, J., Wu, A., Zhu, J., Xu, C., & Liu, X. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00089 · Cited by 80
Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?
Jiang, L., & Schnabl, B. (2020) · Physiology · doi:10.1152/physiol.00005.2020 · Cited by 77
Intestinal Sulfation Is Essential to Protect Against Colitis and Colonic Carcinogenesis
Xu, P., Xi, Y., Zhu, J., Zhang, M., Luka, Z., Stolz, D. B., Cai, X., Xie, Y., Xu, M., Ren, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.03.048 · Cited by 76
Yu, L., Liu, Y., Wang, S., Zhang, Q., Zhao, J., Zhang, H., Narbad, A., Tian, F., Zhai, Q., & Chen, W. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2181930 · Cited by 76
Jiang, J., Gao, Y., Wang, J., Huang, Y., Yang, R., Zhang, Y., Ma, Y., Wen, Y., Luo, G., Zhang, S., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.016 · Cited by 77
Self-citationLi, D., Cui, Y., Wang, X., Liu, F., & Li, X. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c02532 · Cited by 75
Wang, X. X., Xie, C., Libby, A. E., Ranjit, S., Levi, J., Myakala, K., Bhasin, K., Jones, B. A., Orlicky, D. J., Takahashi, S., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102530 · Cited by 75
Self-citationZhang, S., Dong, Y., Wang, P., Zhang, X., Yan, Y., Sun, L., Liu, B., Zhang, D., Zhang, H., Liu, H., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.022 · Cited by 74
Self-citationLi, J., Huo, X., Cao, Y., Li, S., Du, Z., Shao, P., Leng, J., Zhang, C., Sun, X., Ronald, C. W., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.015 · Cited by 74
Self-citationNakada, E. M., Bhakta, N. R., Korwin-Mihavics, B. R., Kumar, A., Chamberlain, N., Bruno, S. R., Chapman, D. G., Hoffman, S. M., Daphtary, N., Aliyeva, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.98101 · Cited by 73
Self-citationZhang, C., Zhou, B.-G., Sheng, J., Chen, Y., Cao, Y.-Q., & Chen, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104984 · Cited by 73
Meadows, V., Kennedy, L. L., Ekser, B., Kyritsi, K., Kundu, D., Zhou, T., Chen, L., Pham, L., Wu, N., Demieville, J., et al. (2021) · Hepatology · doi:10.1002/hep.32028 · Cited by 72
Carino, A., Biagioli, M., Marchianò, S., Fiorucci, C., Zampella, A., Monti, M. C., Scarpelli, P. T., Ricci, P., Distrutti, E., & Fiorucci, S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.07.006 · Cited by 73
Warner, D. R., Warner, J. B., Hardesty, J., Song, Y., King, T. N., Kang, J. X., Chen, C., Xie, S., Yuan, F., Prodhan, M. A. I., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.ra119000200 · Cited by 71
Publisher Correction: The gut–liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0031-8 · Cited by 70
Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease
Grattagliano, I., Montezinho, L. P., Oliveira, P. J., Frühbeck, G., Gómez‐Ambrosi, J., Montecucco, F., Carbone, F., Wieckowski, M. R., Wang, D. Q. ‐., & Portincasa, P. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.020 · Cited by 70
Celastrol Protects From Cholestatic Liver Injury Through Modulation of SIRT1-FXR Signaling
Zhao, Q., Liu, F., Cheng, Y., Xiao, X.-R., Hu, D., Tang, Y., Bao, W.-M., Yang, J., Jiang, T., Hu, J., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000817 · Cited by 69
Self-citationThe Gut Microbiome and Ferroptosis in MAFLD
Ji, J., Wu, L., Wei, J., Wu, J., & Guo, C. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00136 · Cited by 69
Zhu, C., Huai, Q., Zhang, X., Dai, H., Li, X., & Wang, H. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.78525 · Cited by 69
Schumacher, J. D., & Guo, G. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_228 · Cited by 67
Ceramides are fuel gauges on the drive to cardiometabolic disease
Wilkerson, J. L., Tatum, S. M., Holland, W. L., & Summers, S. A. (2024) · Physiological Reviews · doi:10.1152/physrev.00008.2023 · Cited by 67
Takahashi, S., Luo, Y., Ranjit, S., Xie, C., Libby, A. E., Orlicky, D. J., Dvornikov, A. S., Wang, X. X., Myakala, K., Jones, B. A., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011913 · Cited by 67
Self-citationGut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Wittenbecher, C., Cuadrat, R. R. C., Johnston, L., Eichelmann, F., Jäger, S., Kuxhaus, O., Prada, M., Fabiola Del Greco, M., Hicks, A. A., Hoffman, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28496-1 · Cited by 66
Zhang, M., Hu, R., Huang, Y., Zhou, F., Li, F., Liu, Z., Geng, Y., Dong, H., Ma, W., Song, K., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.933110 · Cited by 66
Self-citationOrigins of Portal Hypertension in Nonalcoholic Fatty Liver Disease
Baffy, G. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4903-5 · Cited by 66
Ilan, Y. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00095.2016 · Cited by 65
Zhong, X., Liu, Y., Gao, X., Krausz, K. W., Niu, B., Gonzalez, F. J., & Xie, C. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00921-7 · Cited by 64
Self-citationDietary and metabolic effects on intestinal stem cells in health and disease
Shay, J. E. S., & Yilmaz, Ö. H. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00980-7 · Cited by 65
Liu, W., Wang, J., Yang, H., Li, C., Lan, W., Chen, T., & Tang, Y. (2025) · Advanced Science · doi:10.1002/advs.202413010 · Cited by 64
Nakagawa, H. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i17.2110 · Cited by 63
Intestinal MYC modulates obesity-related metabolic dysfunction
Luo, Y., Yang, S., Wu, X., Takahashi, S., Sun, L., Cai, J., Krausz, K. W., Guo, X., Dias, H. B., Gavrilova, O., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00421-8 · Cited by 63
Self-citationGut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease
Zhou, J., Tripathi, M., Sinha, R. A., Singh, B. K., & Yen, P. M. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2020.134 · Cited by 63
Studies of xenobiotic-induced gut microbiota dysbiosis: from correlation to mechanisms
Chi, L., Tu, P., Ru, H., & Lü, K. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1921912 · Cited by 61
Kuraji, R., Shiba, T., Dong, T. S., Numabe, Y., & Kapila, Y. L. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.967 · Cited by 63
Hu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 61
Jena, P. K., Sheng, L., Nagar, N., Wu, C., Barile, D., Mills, D. A., & Wan, Y.-J. Y. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.04.007 · Cited by 60
Li, R., Liu, Y., Shi, J., Yu, Y., Lu, H., Yu, L., Liu, Y., & Zhang, F. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.04.010 · Cited by 61
Li, Z., Yuan, H., Chu, H., & Yang, L. (2023) · Microorganisms · doi:10.3390/microorganisms11082059 · Cited by 60
Somm, E., Henry, H., Bruce, S. J., Aeby, S., Rosikiewicz, M., Sykiotis, G. P., Asrih, M., Jornayvaz, F. R., Denechaud, P. D., Albrecht, U., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91809 · Cited by 56
Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies
Leylabadlo, H. E., Ghotaslou, R., Kafil, H. S., Feizabadi, M. M., Moaddab, S. Y., Farajnia, S., Sheykhsaran, E., Sanaie, S., Shanehbandi, D., & Baghi, H. B. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03746-1 · Cited by 60
The Circadian Clock as an Essential Molecular Link Between Host Physiology and Microorganisms
Murakami, M., & Tognini, P. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00469 · Cited by 60
Li, X., Zhao, W., Meng, X., Yu, L., Chen, Q., Hu, X., Zhao, Y., Xiong, L., Chen, X., Wang, X., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115333 · Cited by 61
Pi, Y., Fang, M., Li, Y., Cai, L., Han, R., Sun, W., Jiang, X., Chen, L., Du, J., Zhu, Z., et al. (2024) · Nutrients · doi:10.3390/nu16172838 · Cited by 60
Modulation of Lipid Metabolism by Celastrol
Zhang, T., Zhao, Q., Xiao, X., Yang, R., Hu, D., Zhu, X., Gonzalez, F. J., & Li, F. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00797 · Cited by 58
Self-citationTranscriptional Regulation in Non-Alcoholic Fatty Liver Disease
Steensels, S., Qiao, J., & Ersoy, B. A. (2020) · Metabolites · doi:10.3390/metabo10070283 · Cited by 58
The pathophysiological function of non-gastrointestinal farnesoid X receptor
Yan, N., Yan, T., Xia, Y., Hao, H., Wang, G., & Gonzalez, F. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107867 · Cited by 58
Self-citationAflatoxin B1 induces liver injury by disturbing gut microbiota-bile acid-FXR axis in mice
Liu, Y., Li, J., Kang, W., Liu, S., Liu, J., Shi, M., Wang, Y., Liu, X., Chen, X., & Huang, K. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113751 · Cited by 57
Dai, H., Shan, Z., Shi, L., Duan, Y., An, Y., He, C., Lyu, Y., Zhao, Y., Wang, M., Du, Y., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136876 · Cited by 58
The Role of the Gut Microbiota in Sustained Weight Loss Following Roux-en-Y Gastric Bypass Surgery
Fouladi, F., Brooks, A. E., Fodor, A. A., Carroll, I. M., Bulik‐Sullivan, E. C., Tsilimigras, M. C. B., Sioda, M., & Steffen, K. J. (2019) · Obesity Surgery · doi:10.1007/s11695-018-03653-y · Cited by 57
Ni, Y., Ni, L., Zhuge, F., & Fu, Z. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000375 · Cited by 57
Jadhav, K., & Cohen, T. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.592157 · Cited by 53
Shapiro, H., Suez, J., & Elinav, E. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12501 · Cited by 56
“and insulin resistance and were protected against the development of fatty liver.(72,73) Blocking intestinal FXR by administration of an FXR antagonist modified bile”
BackgroundLi, Y., Nicholson, R. J., & Summers, S. A. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111554 · Cited by 56
Zhai, Y., Zhou, W., Yan, X., Qiao, Y., Guan, L., Zhang, Z., Liu, H., Jiang, J., Liu, J., & Peng, L. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154444 · Cited by 56
Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases
Jia, E., Liu, Z.-Y., Pan, M., Lu, J., & Ge, Q. (2019) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1900073 · Cited by 58
Yu, X.-D., & Wang, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115157 · Cited by 56
NAFLD, Helicobacter species and the intestinal microbiome
Castaño‐Rodríguez, N., Mitchell, H. M., & Kaakoush, N. O. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.09.008 · Cited by 55
Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases
Malhi, H., & Camilleri, M. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.09.008 · Cited by 55
Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
Li, C., Yang, J., Wang, Y., Qi, Y., Yang, W., & Li, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01247 · Cited by 55
Self-citationHe, L., Yao, D.-H., Wang, L., Zhang, L., & Bai, X. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.761836 · Cited by 56
Self-citationThe role of bile acids in regulating glucose and lipid metabolism
Yu, H., Nie, R., & Shen, C. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej22-0544 · Cited by 54
Perilipin-2 Modulates Lipid Absorption and Microbiome Responses in the Mouse Intestine
Frank, D. N., Bales, E. S., Monks, J., Jackman, M. J., MacLean, P. S., Ir, D., Robertson, C. E., Orlicky, D. J., & McManaman, J. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131944 · Cited by 47
Association between endotoxemia and histological features of nonalcoholic fatty liver disease
Kitabatake, H., Tanaka, N., Fujimori, N., Komatsu, M., Okubo, A., Kakegawa, K., Kimura, T., Sugiura, A., Yamazaki, T., Shibata, S., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i4.712 · Cited by 53
Self-citationReciprocal interactions between bile acids and gut microbiota in human liver diseases
Ikegami, T., & Honda, A. (2018) · Hepatology Research · doi:10.1111/hepr.13001 · Cited by 55
Zhao, H.-L., Wu, H., Duan, M., Liu, R., Quanhong, Z., Zhang, K., & Wang, L. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s288011 · Cited by 54
Yamada, S., Kamada, N., Amiya, T., Nakamoto, N., Nakaoka, T., Kimura, M., Saito, Y., Ejima, C., Kanai∥, T., & Saito, H. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0689-3 · Cited by 53
Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD
Poss, A. M., & Summers, S. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00505 · Cited by 54
Molecular Biomarkers for Gestational Diabetes Mellitus and Postpartum Diabetes
Lu, W., & Hu, C. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002160 · Cited by 52
“As a potent farnesoid X receptor antagonist, tauro-b-muricholic acid inhibits intestinal farnesoid X receptor signaling, contributing to improved hepatic steatosis, insulin sensitivity, and glucose tolerance.([72,73])”
BackgroundKayser, B. D., Prifti, E., Lhomme, M., Belda, E., Dao, M. C., Aron‐Wisnewsky, J., Cotillard, A., Kennedy, S., Pons, N., Chatelier, E. L., et al. (2019) · Metabolomics · doi:10.1007/s11306-019-1596-0 · Cited by 53
Clinical implications of understanding the association between oxidative stress and pediatric NAFLD
Mann, J. P., Raponi, M., & Nobili, V. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1291340 · Cited by 52
Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
Takahashi, S., Tanaka, N., Fukami, T., Xie, C., Yagai, T., Kim, D., Velenosi, T. J., Yan, T., Krausz, K. W., Levi, M., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1263 · Cited by 50
Self-citationHong, J. T., Lee, M.-J., Yoon, S. J., Shin, S. P., Bang, C. S., Baik, G. H., Kim, D. J., Youn, G. S., Shin, M. J., Ham, Y. L., et al. (2020) · Journal of Ginseng Research · doi:10.1016/j.jgr.2020.07.004 · Cited by 50
Natural and synthetic retinoid X receptor ligands and their role in selected nuclear receptor action
Brtko, J., & Dvořák, Z. (2020) · Biochimie · doi:10.1016/j.biochi.2020.09.027 · Cited by 50
Ding, L., Zhang, E., Yang, Q., Jin, L., Sousa, K. M., Dong, B., Wang, Y., Tu, J., Ma, X., Tian, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019388118 · Cited by 50
Self-citationIntestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease
Nawrot, M., Peschard, S., Lestavel, S., & Staels, B. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154844 · Cited by 51
m6A modification-tuned sphingolipid metabolism regulates postnatal liver development in male mice
Wang, S., Chen, S., Sun, J., Han, P., Xu, B., Li, X., Zhong, Y., Xu, Z., Zhang, P., Mi, P., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00808-9 · Cited by 51
Kayser, B. D., Lhomme, M., Dao, M. C., Ichou, F., Bouillot, J., Prifti, E., Kontush, A., Chevallier, J., Aron‐Wisnewsky, J., Dugail, I., et al. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.63 · Cited by 49
Shima, K. R., Ota, T., Kato, K., Takeshita, Y., Misu, H., Kaneko, S., & Takamura, T. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000469 · Cited by 49
Chen, S., Sun, S., Feng, Y., Li, X., Yin, G., Liang, P., Yu, W., Meng, D., Zhang, X., Liu, H., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175808 · Cited by 50
Nakanishi, T., Fukui, H., Wang, X., Nishiumi, S., Yokota, H., Makizaki, Y., Tanaka, Y., Ohno, H., Tomita, T., Oshima, T., et al. (2021) · Cells · doi:10.3390/cells10113168 · Cited by 48
Current and Potential Therapies Targeting Inflammation in NASH
Albhaisi, S. A. M., & Noureddin, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.767314 · Cited by 48
Zheng, X., Xu, X., Liu, M., Yang, J., Yuan, M., Sun, C., Zhou, Q., Chen, J., & Liu, B. (2024) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2024.109376 · Cited by 47
The critical roles of bioactive sphingolipids in inflammation
Gómez-Larrauri, A., Larrea, A., Martín, C., & Gómez‐Muñoz, A. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110475 · Cited by 47
Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease
Hundertmark, J., Krenkel, O., & Tacke, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02418 · Cited by 44
Ceramide and Sphingosine 1-Phosphate in Liver Diseases.
Park, W., Song, J.-H., Kim, G., & Park, T. (2020) · PubMed Central · doi:10.14348/molcells.2020.0054 · Cited by 47
The contribution of the gut-liver axis to the immune signaling pathway of NAFLD
Liu, J., Wu, A., Cai, J., She, Z., & Li, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968799 · Cited by 47
Self-citationRoles of Ileal ASBT and OSTα-OSTβ in Regulating Bile Acid Signaling
Dawson, P. A. (2017) · Digestive Diseases · doi:10.1159/000450987 · Cited by 47
Tissue-specific mechanisms of fat metabolism that focus on insulin actions
Wu, S., Tan, J., Zhang, H., Hou, D., & He, J. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.12.009 · Cited by 46
Zhao, Y., Gao, L., Chen, J., Wei, J., Lin, G., Hu, K., Zhao, W., Wei, W., Huang, W., Gao, L., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.02.009 · Cited by 47
Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view
Chen, H., Huang, H., Li, Y., Xu, H., & Zhou, Y. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i16.1901 · Cited by 46
Ahmad, M. I., Ijaz, M. U., Hussain, M., Haq, I. U., Zhao, D., & Li, C. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c02570 · Cited by 47
Bile Acids, Microbiota, and Metabolism
Taylor, S. A., & Green, R. M. (2018) · Hepatology · doi:10.1002/hep.30078 · Cited by 46
Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics
Cho, M. S., Kim, S. Y., Suk, K. T., & Kim, B. (2018) · The Journal of Microbiology · doi:10.1007/s12275-018-8346-2 · Cited by 46
The Liver under the Spotlight: Bile Acids and Oxysterols as Pivotal Actors Controlling Metabolism
Lefort, C., & Cani, P. D. (2021) · Cells · doi:10.3390/cells10020400 · Cited by 42
Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases
Liu, J., Yang, D., Wang, X., Asare, P. T., Zhang, Q., Na, L., & Shao, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.774335 · Cited by 45
Lin, C., Huang, X., Liu, H., & Wang, Y. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3772-z · Cited by 45
Metadata
- Authors
- Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., Tanaka, N., Desai, D., Amin, S. G., Albert, I., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Pennsylvania State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-12-15
- Volume
- 125
- Issue
- 1
- Pages
- 386-402
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4382255
- OpenAlex
- W2124025733
- Cited by
- 693
- References
- 68
- Citations by year
- 2026: 43 · 2025: 52 · 2024: 52 · 2023: 61 · 2022: 76 · 2021: 84 · 2020: 70 · 2019: 63 · 2018: 58 · 2017: 61 · 2016: 46 · 2015: 26
- FWCI
- 33.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- non-alcoholic fatty liver disease, gut microbiota, bile acids, bile acid conjugates, ceramide, ceramide synthesis, SREBP-1c, de novo lipogenesis, hepatic steatosis, high-fat diet, antibiotic therapy, tempol, nuclear receptor signaling, therapeutic target
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anti-Bacterial Agents, Bile Acids and Salts, Cecum, Gene Expression Regulation, Humans, Ileum, Liver, Male, Mice, Inbred C57BL, Mice, Transgenic, Gene Expression, Receptors, Cytoplasmic and Nuclear, Lipid Metabolism, Metabolic Networks and Pathways, Diet, High-Fat, Mitochondrial Dynamics, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.